V

Varian

Tech-enabled radiation oncology hardware and software

Director of Assay Development and Consumables Integration - Handheld Systems

Full-Time
CA$110k - CA$157k
Expert
Bachelor's
Ottawa, ON, Canada
In Person
Biology & BiotechBiomedical Engineering & Medical Devices

About the job

Requirements
  • A bachelor's degree in Chemistry, Biochemistry, Biomedical Engineering, Chemical Engineering, Engineering, or a related field is required; an advanced degree is strongly preferred.
  • At least 12 years of progressive experience in the in vitro diagnostics or medical device industry is required.
  • Experience with electrochemical sensor development, reagent chemistry optimization, and microfluidics is required.
  • Experience with high-volume consumable manufacturing processes, such as injection molding and automation equipment, is required.
  • Demonstrated success bringing point-of-care diagnostics products to market is required.
  • Working knowledge of design controls and global regulations, including FDA Quality System Regulations, ISO 13485, IVDR, and ISO 14971 risk management, is required.
  • Ability to lead multidisciplinary R&D teams, develop talent, and build a culture of scientific excellence, accountability, and innovation is required.
  • Ability to collaborate and influence senior stakeholders across R&D, Quality, Regulatory, Manufacturing, Marketing, and external partners is required.
  • A proactive, data-driven approach to problem solving and project management, including navigating complex technical challenges, managing ambiguity, and driving decisions with cross-functional input, is required.
  • A systems-thinking approach and ability to integrate assay chemistry, consumables engineering, hardware, and software into a reliable diagnostic system is required.
Responsibilities
  • Manage, mentor, and develop a multidisciplinary team of scientists and engineers specializing in assay chemistry and consumable development.
  • Foster scientific rigor, collaboration, accountability, and continuous improvement, and represent the team on the Handheld Systems R&D leadership team to shape product strategy and align with business goals.
  • Own end-to-end development of next-generation blood gas assays, including test-menu expansion, and associated consumables such as test cards and sample collection devices.
  • Establish product requirements and specifications using sound science, statistical methods, and industry best practices.
  • Integrate assay chemistry with consumable design to ensure assays meet requirements in their consumable format and in the overall device system.
  • Partner with the Systems Development & Integration team to achieve hardware-software-assay interoperability and robust system performance.
  • Collaborate with the Assay Performance (Lifecycle Engineering) team on sensor calibration and data analytics to ensure new assay and consumable designs meet system performance requirements.
  • Provide technical leadership for sustaining and continuously improving on-market assays and consumables.
  • Own design changes resulting from part, material, or reagent obsolescence, including risk assessment, change control, product performance, and regulatory compliance.
  • Oversee robust manufacturing process development and control of Critical-to-Quality attributes in high-volume production; work with Manufacturing, Supply Chain, Quality, and Regulatory teams on scalable production, technical design transfers, and continuous supply.
  • Ensure development and sustaining activities follow global in vitro diagnostics regulatory standards, including FDA Quality System Regulations, ISO 13485, IVDR, CLSI, and ISO 14971 risk management.
  • Maintain design history files and risk management documentation for assays and consumables.
  • Resolve cross-functional challenges and make decisions that balance innovation speed with compliance and reliability.
  • Define and track key performance indicators, including assay performance metrics, consumable yield and cost, and project milestones, to improve development velocity, product quality, and reliability.
Desired Qualifications
  • An advanced degree is strongly preferred.

About the company

Varian, part of Siemens Healthineers, focuses on oncology by providing integrated radiation oncology solutions that combine software, hardware, patient data, and care teams. Its offerings include treatment-planning software, radiation therapy machines, and data-management systems that work together to enable precise cancer treatments. The company differentiates itself through an integrated platform approach and services like Oncology-as-a-Service (OaaS), which lets healthcare providers adopt advanced radiation oncology with ongoing service support rather than large upfront investments. Varian serves healthcare providers such as hospitals and cancer centers, helping them deliver coordinated care and improve patient outcomes. Its goal is to reduce the fear of cancer by using data and technology to support clinicians in delivering effective treatments.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Palo Alto, California

Founded

1948

Get referred to Varian

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • ARPA-H awarded Varian up to $60 million in April 2026 for FLASH-RT.
  • FDA cleared TrueBeam for osteoarthritis in March 2026, opening a non-cancer market.
  • Telix collaboration and 2026 AI approvals expand Varian's clinical and software pipeline.

What critics are saying

  • RaySearch enabled online adaptive TrueBeam workflows in Belgium in May 2026, eroding software differentiation.
  • Elekta still attacks Varian's lead in adaptive radiotherapy and premium MR-guided care.
  • If FLASH and non-oncology bets fail by 2028, Varian becomes a commoditized linear-accelerator vendor.

What makes Varian unique

  • Siemens Healthineers gives Varian imaging, radiotherapy, and capital-sales integration globally.
  • Varian's 2026 CE-marked Eclipse AI contouring deepens workflow lock-in across planning.
  • TrueBeam, Halcyon, and Ethos create an installed-base moat hospitals rarely replace.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Holidays

Health Insurance

Dental Insurance

Vision Insurance

Wellness Program

401(k) Retirement Plan

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

3%

2 year growth

3%
Varex Imaging Corporation
Sep 14th, 2026
About Us | Varex Imaging Corporation

We strive to help customers become world-class system suppliers by strengthening their competitiveness and enabling them to bring products to market faster

MEDQOR
Apr 30th, 2026
Siemens Healthineers secures $83M to develop photon Flash radiotherapy for cancer treatment

Siemens Healthineers has received up to $60 million from the US Advanced Research Projects Agency for Health to develop photon Flash radiotherapy, with the company contributing an additional $23 million, totalling $83 million over five years. Flash photon therapy delivers radiotherapy more than 100 times faster than current technologies, aiming to reduce side effects and improve healthy tissue sparing. Unlike proton and electron beam platforms, which face scalability challenges, photon beams are the standard of care for over 50% of cancer patients. The project will build on existing C-arm linear accelerators to enable broader clinical access. Siemens Healthineers aims to transition ultra-high dose rate radiotherapy from experimental treatment into global standard of care within the five-year timeframe.

Business Wire
Mar 19th, 2026
Varian TrueBeam gets FDA clearance for low-dose radiotherapy to treat osteoarthritis

Siemens Healthineers has received FDA 510(k) clearance for its Varian TrueBeam radiotherapy systems to treat medically refractory osteoarthritis in adults using low-dose radiation therapy. This marks the first expansion of Varian's radiotherapy platform beyond cancer care into chronic musculoskeletal conditions. Osteoarthritis affects over 33 million adults in the US and approximately 600 million globally. The clearance covers TrueBeam, TrueBeam STx, VitalBeam and Edge systems, offering patients with persistent pain a non-invasive outpatient treatment option that targets inflammation, reduces pain and improves joint function. The approval builds on Varian's previous regulatory clearances for non-oncological indications, including radiosurgery treatment for medically refractory essential tremor. The TrueBeam platform combines high-resolution imaging with precise dose control whilst maintaining streamlined clinical workflows.

AuntMinnieEurope.com
Dec 10th, 2025
Telix and Varian enter research collaboration

Telix and Varian enter research collaboration. Telix Pharmaceuticals and Siemens Healthineers' company Varian have agreed to develop novel clinical applications that combine Telix's theranostics products and Varian's external beam radiation therapy (EBRT) technology. The first area of focus will be in identifying opportunities to use Telix's prostate cancer PET imaging agents in selecting patients for EBRT, developing personalized treatment plans (particularly in the context of Varian's Ethos adaptive radiotherapy system), and monitoring responses to treatment, Telix said. The agreement supports both company-sponsored and investigator-led clinical studies. Varian is a key player in EBRT and working with the company will allow Telix to explore how theranostics can be used more effectively by radiation oncologists to enhance patient selection and deliver targeted treatment, Telix noted. I agree to receive marketing related digital communications about products, services, events and offers that may be relevant to my given user preferences and behavior. I agree to share my information with the sponsor. I have read and agree to the privacy policy & terms of service and wish to opt-in.

AuntMinnie.com
Mar 28th, 2025
Varian, Embolx sign image-guided microcatheter agreement

Siemens Healthineers company Varian has entered into a sales and marketing agreement with Embolx for its Sniper Balloon Occlusion Microcatheter.